Pulsatile drug delivery system using core-in-cup approach: a review

Trupti Shashikant Jadhav, Nilima A. Thombre, Sanjay J. Kshirsagar


Oral controlled drug delivery systems represent the most popular form of controlled drug delivery systems for the obvious advantages of oral route of drug administration. Such systems release the drug with constant or variable release rates. Pulsatile drug delivery system (PDDS) can be defined as a system where drug is released suddenly after a well-defined lag time according to the circadian rhythm of the disease. PDDS can be classified according to the pulse-regulation of drug release into three main classes; time-controlled pulsatile release (single or multiple unit system), internal stimuli- induced release and external stimuli-induced pulsatile release systems. Pulsatile delivery is generally intended as a release of the active ingredient that is delayed for a programmable period of time to meet particular chronotherapeutic needs and, in the case of oral administration, also target distal intestinal regions, such as the colon. Most oral pulsatile delivery platforms consist in coated formulations wherein the applied polymer serves as the release-controlling agent. When exposed to aqueous media, the coating initially performs as a protective barrier and, subsequently, undergoes a timely failure based on diverse mechanisms depending on its physico-chemical and formulation characteristics.


Pulsatile drug delivery system, Core-in-cup approach, Inlay tablets

Full Text:



Chien YW. Novel drug delivery system. 2nd ed, Marcel Decker Inc., New York; 2005: 1-3.

Davis SS, Illum L. Drug delivery systems for challenging molecules. Int J Pharm. 1998;176:1-8.

Bussemer T, Bodmeier RA. Drug delivery Pulsatile. Encyclopaedia of pharmaceutical technology; 2006: 1287-1297.

Bjorn L. The importance of circadian rhythms on drug response in hypertension and coronary heart diseases. Pharmacology and therapeutics. 2006;111:629-65.

Bruguerolle B, Labrecque G et al. Rhythmic pattern in pain and their chronotherapy. Adv Drug Del Rev. 2007;59:883-95.

Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery current perspective. J Controlled Rel. 2009;134:74-80.

Smolensky MH, Lemmer B et al. Chronobiology and chronotherapeutics of allergic rhinitis and bronchial asthma. Ame J Res Cri Care Med. 2007;59:852-82.

Gazzaniga A, Palugan L, Foppoli A, Sangalli ME. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm. 2008;68:11-8.

Fort J. Celecoxib, a COX-2-specific inhibitor: the clinical data. Am J Orthop. 1999;28(3):13-8.

Geis GS. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect. Scand J Rheumatol. 1999;109:31-7.

Goldenberg MM. Celecoxib, a selective cyclooxygenase-2-inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther. 1991;21(9):1497-513.

Prashant AB, Bushetti SS, Najmuddin M. Formulation and evaluation of pulsatile drug delivery system of Metoprolol tartarate using core in cup tablet. Am J Med Med Sci. 2012;2(6):114-22.

Gao W, Zhonghong WU, Chen Q, Bin YU. Preparation of Candesartan celexitil core in cup tablets with pulsatile release properties and its effects on the blood pressure of rabbits. J China Pharm Uni. 2010;41(2):124-9.

Khadabadi SS, Nahid HC, Farhan MK, Akeel AT. Formulation and evaluation of press coated tablet of ketoprofen- a chronotherapeutic approach. Int J Pharm Pharm Sci. 2012;5(3):733-40.

Li CJ, Zhu JB, Yu WY. Preparation of verapamil hydrochloride core-in-cup tablets with double-pulsatile and multi-phasic release. 2008;43(6):652-6.

Archana SP, Panchaxari MD, Vinayak SM, Anand PG, Basavaraj KN. Development and characterization of chronomodulated drug delivery system of captopril. Int J Pharm Inv. 2011;1(4):227-33.

Swati J, Monali S, Ajay B, Janardan L, Bhanudas K, Anuruddha C. Development of pulsatile release tablets of atenolol with swelling and rupturable layers. Int J Pharm. 2010;2(3):31-40.

Rane AB, Gattani SG, Kadam VD, Tekade AR. Formulation and evaluation of press coated tablets for pulsatile drug delivery using hydrophilic and hydrophobic polymers. Chem Pharm Bull (Tokyo). 2009;57(11):1213-7.

Mastiholimath VS, Dandagi PM, Samata SJ, Gadad AP, Kulkarni AR. Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma, Int journal pharma. 2007;328: 49-56.

Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, et al. An organic acid induced sigmoidal release system for oral controlled-release preparations. Pharma Research. 1994;11(1):111-6.

Patel MM et al. Design, development and optimization of a novel time and pHdependent colon targeted drug delivery system. Pharmaceutical development and technology. 2009;14(1):65-72.

Balaban SM, Pike JB, Smith JP, Baile CA, Delivery devices with pulsatile effect, Google Patents; 1994.

Bechegaard H, Nielson GH. Controlled Release Multiple Unit and Single Unit Doses. Drug Dev Ind Pharm. 1978;4:53-67.

Beckert TE, Pogarell K, Hack I, Petereit H-U, Pulsed drug release with film coatings of Eudragit & Mac226; RS 30D. Precede Int. Symp Control Release Bioact Mater. 1999;26:533-4.

Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Crit. Review Ther Drug Carrier System. 2001;18(5):433-58.

Chan LW, Chan WY, Heng PWS. An improved method for the measurement of colour uniformity in pellet coating, International Journal of Pharmaceutics. 2001;213:63-74.

Chaurasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Journal Pharm Pharmaceutica Science. 2004;11:129-48.

Chirag RK, Guo X, Burside BA, Couch RA, Rudnic EM. Formulation approaches for oral pulsatile drug delivery, American Pharma Review. 1999;2(1):51-7.

Chirag RK, Guo X, Burside BA, Couch RA, Rudnic EM. Formulation approaches for oral pulsatile drug delivery. American Pharma Review. 1999;2(1):21.

Dalvadia H, Patel JK. Chronpharmaceutics, Pulsatile drug delivery system as current trend. Asian journal pharm Science. 2010;5:204-30.


  • There are currently no refbacks.

Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations